Comparison of the Peroxidase Reaction Kinetics of Prostaglandin H Synthase-1 and -2*

Guqiang LuDagger , Ah-Lim TsaiDagger , Harold E. Van Wart§, and Richard J. KulmaczDagger

From the Dagger  Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas 77030 and the § Inflammatory Diseases Unit, Roche Bioscience, Palo Alto, California 94304

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Prostaglandin H synthase isoforms 1 and 2 (PGHS-1 and -2) each have a peroxidase activity and also a cyclooxygenase activity that requires initiation by hydroperoxide. The hydroperoxide initiator requirement for PGHS-2 cyclooxygenase is about 10-fold lower than for PGHS-1 cyclooxygenase, and this difference may contribute to the distinct control of cellular prostanoid synthesis by the two isoforms. We compared the kinetics of the initial peroxidase steps in PGHS-1 and -2 to quantify mechanistic differences between the isoforms that might contribute to the difference in cyclooxygenase initiation efficiency. The kinetics of formation of Intermediate I (an Fe(IV) species with a porphyrin free radical) and Intermediate II (an Fe(IV) species with a tyrosyl free radical, thought to be the crucial oxidant in cyclooxygenase catalysis) were monitored at 4°c by stopped flow spectrophotometry with several hydroperoxides as substrate. With 15-hydroperoxyeicosatetraenoic acid, the rate constant for Intermediate I formation (k1) was 2.3 × 107 M-1 s-1 for PGHS-1 and 2.5 × 107 M-1 s-1 for PGHS-2, indicating that the isoforms have similar initial reactivity with this lipid hydroperoxide. For PGHS-1, the rate of conversion of Intermediate I to Intermediate II (k2) became the limiting factor when the hydroperoxide level was increased, indicating a rate constant of 102-103 s-1 for the generation of the active cyclooxygenase species. For PGHS-2, however, the transition between Intermediates I and II was not rate-limiting even at the highest hydroperoxide concentrations tested, indicating that the k2 value for PGHS-2 was much greater than that for PGHS-1. Computer modelling predicted that faster formation of the active cyclooxygenase species (Intermediate II) or increased stability of the active species increases the resistance of the cyclooxygenase to inhibition by the intracellular hydroperoxide scavenger, glutathione peroxidase. Kinetic differences between the PGHS isoforms in forming or stabilizing the active cyclooxygenase species can thus contribute to the difference in the regulation of their cellular activities.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Prostaglandins have roles in a variety of pathophysiological processes, including inflammation, hemostasis, gastric cytoprotection, and pain sensation (1). Prostaglandin H synthase (PGHS)1 catalyzes the first committed step in prostaglandin biosynthesis, the conversion of arachidonic acid to PGG2, called the cyclooxygenase reaction (2). PGHS also has a heme-dependent peroxidase activity that reduces the C15 hydroperoxide of PGG2 to a hydroxyl, producing prostaglandin H2, the precursor of all other prostanoids (2). Two PGHS isoforms have been identified, termed PGHS-1 and PGHS-2 (3). PGHS-1 is present at essentially constitutive levels in a wide variety of cells, whereas PGHS-2 is undetectable in most quiescent cells but can be strongly induced in some cells by cytokines and mitogens (3). This very different control of expression of the two distinct PGHS genes has led to the concept that the isoforms serve distinct physiological functions, with PGHS-1 assigned a housekeeping role and PGHS-2 implicated in cytokine-mediated events (3). Cellular prostaglandin synthesis is also tightly regulated at the level of cyclooxygenase catalysis (4). This catalytic regulation is particularly interesting because it appears to be different for the two isoforms. In many cells containing both isoforms, the PGHS-2 cyclooxygenase has been found to be catalytically active at the same time that the PGHS-1 cyclooxygenase remains latent (4). One possible biochemical explanation for such differential cellular catalytic control of the two isoforms is their different hydroperoxide activator requirements, with the PGHS-2 cyclooxygenase activated at lower hydroperoxide levels than the PGHS-1 cyclooxygenase (5, 6). Because of this potential to influence cellular control of prostanoid synthesis, it is important to define the mechanistic basis for the difference in activator efficiency between the two PGHS isoforms.

Conversion of latent cyclooxygenase to catalytically competent enzyme is believed to involve formation of a key catalytic component, a free radical located on Tyr385 (Tyr371 in PGHS-2) in the upper part of the cyclooxygenase channel (7-12). In this mechanism (depicted in Scheme I), generation of the active tyrosyl radical involves an initial reaction of a hydroperoxide with the peroxidase site heme to form Intermediate I, analogous to Compound I in horseradish peroxidase. Intermediate I is oxidized by two equivalents compared with the resting ferric enzyme. An intramolecular one-electron transfer from Tyr385 to the heme subsequently produces the tyrosyl radical (Intermediate II), which has one oxidizing equivalent on Tyr385 and one on the ferryl heme. Intermediate II, with its tyrosyl radical, is thought to be the initial oxidant in cyclooxygenase catalysis (7). In the present studies, we have used stopped flow spectroscopic measurements to characterize the kinetics of the reactions of PGHS-1 and -2 with several peroxides, with a focus on the steps leading to formation of Intermediate II. The results show that formation of this crucial cyclooxygenase intermediate is considerably faster for PGHS-2 than for PGHS-1, accounting in part for the more efficient cyclooxygenase activation in PGHS-2.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Glutathione, GSP, glycerol, hemin chloride, and Pharmalytes (pH 5-8) were from Sigma. PD-10 desalting columns were from Supelco. EtOOH was from Polysciences, and PPHP was purchased from Cayman Chemicals. Arachidonic acid was obtained from NuChek Preps and was routinely used without borohydride treatment. Tween 20 was obtained as a 10% solution from Pierce, and octyl-beta -D-glucopyranoside was from Amresco (Solon, OH).

PGHS-1 was purified from ram seminal vesicles (13). Recombinant human PGHS-2 was expressed in cultured insect cells and purified to homogeneity as previously reported (6). Protein concentrations were determined as described by Peterson (14). The holoenzymes were reconstituted by addition of heme (1.4 mol/mol subunit), followed by treatment with DEAE-cellulose and gel filtration chromatography on a PD-10 column to remove excess heme and to exchange buffer (15). The holoenzyme concentrations were determined from their absorbance at 410 nm (165 mM-1 cm-1). 15-HPETE was prepared from arachidonic acid by reaction with soybean lipoxygenase (16) and purified by high pressure liquid chromatography (17). The purity of the 15-HPETE was assessed chromatographically, and the concentration was quantitated from the oxidation of N,N,N',N'-tetramethyl-p-phenylenediamine in the presence of excess PGHS-1 (18).

Stopped flow kinetic studies were conducted at 4 °C on a Bio-Sequential DX-18MV stopped flow instrument (Applied Photophysics, Leatherhead, Surrey, UK) as described previously (19), using equal volume mixing. The Soret maximum of resting enzyme (410 nm for PGHS-1 and 408 nm for PGHS-2) was used to monitor the formation of Intermediate I. Formation of Intermediate II was monitored for both isoforms at 424 nm, near the isosbestic point between resting enzyme and Intermediate I in PGHS-1 (7, 19). Reaction rates were obtained by fitting averaged kinetic data from at least three replicate runs to an exponential function. Both holoenzyme and peroxide were generally diluted in a 0.1 M potassium phosphate, pH 7.3, containing 10% glycerol, 0.1% Tween 20, and 0.1% octyl-beta -D-glucopyranoside.

Computer simulations of cyclooxygenase kinetics in the presence of added GSP were carried out by numerical integration using the SCoP program (Simulation Resources, Redlands, CA). Calculations were based on the PGHS mechanism shown in Scheme II, with separate provisions for GSP activity. The mechanism is based on the branched chain tyrosyl radical mechanism proposed by Dietz et al. (7), with addition of two enzyme intermediates (E(III)/PPIX/Tyr* and E(IV)/PPIX*/Tyr*) to allow continued peroxidase activity at the heme site after formation of the tyrosyl radical in the cyclooxygenase site. The rate equations used in the SCoP program were as follows.
<UP>d</UP>[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP>]<UP>/dt</UP>=<UP>−</UP>k<SUB>1</SUB>[<UP>ROOH</UP>][<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP>]+k<SUB>4</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr</UP>]+k<SUB>6</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>] (Eq. 1)
<UP>d</UP>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr</UP>]<UP>/dt</UP>=k<SUB>1</SUB>[<UP>ROOH</UP>][<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP>]
           −k<SUB>2</SUB>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr</UP>]−k<SUB>3</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr</UP>]
           +k<SUB>6</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>] (Eq. 2)
<UP>d</UP>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr</UP>]<UP>/dt</UP>=k<SUB>3</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr</UP>]−k<SUB>4</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr</UP>]+k<SUB>6</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>] (Eq. 3)
<UP>d</UP>[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]<UP>/dt</UP>=<UP>−</UP>k<SUB>1</SUB>[<UP>ROOH</UP>][<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]
+k<SUB>4</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>]−k<SUB>6</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]
       −k<SUB>7</SUB>[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>] (Eq. 4)
<UP>d</UP>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>]<UP>/dt</UP>=k<SUB>1</SUB>[<UP>ROOH</UP>][<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]
−k<SUB>3</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>]−k<SUB>6</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>]
       −k<SUB>7</SUB>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>] (Eq. 5)
<UP>d</UP>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>]<UP>/dt</UP>=k<SUB>2</SUB>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr</UP>]
       <UP>   +k</UP><SUB><UP>3</UP></SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>] −k<SUB>4</SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>]
−k<SUB><UP>6</UP></SUB>[<UP>AH</UP>][<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Try*</UP>]<UP>−<B>k</B></UP><SUB><UP>7</UP></SUB>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Try*</UP>] (Eq. 6)
d[E(inact)]/dt=k<SUB><UP>7</UP></SUB>([<UP>E</UP>(<UP>II</UP>)<UP>/PPIX/Try*</UP>]<UP>+</UP>[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Try*</UP>]
 +[E(IV)/PPIX/Try*]) (Eq. 7)
<UP>d</UP>[<UP>AA</UP>]<UP>/dt</UP>=<UP>−</UP>k<SUB>5</SUB>([<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]+[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>]
 +[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>])<UP>/</UP>(<UP>1</UP>+K<SUB>m<UP>AA</UP></SUB><UP>/</UP>[<UP>AA</UP>]) (Eq. 8)
<UP>d</UP>[<UP>ROOH</UP>]<UP>/dt</UP>=k<SUB>5</SUB>([<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]+[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>]
 +[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>])<UP>/</UP>(<UP>1</UP>+K<SUB>m<UP>AA</UP></SUB><UP>/</UP>[<UP>AA</UP>])−k<SUB>1</SUB>[<UP>ROOH</UP>]([<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP>]
 +[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>])−R<SUB><UP>GC</UP></SUB>k<SUB>5</SUB>[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP><SUB>0</SUB>]/(1+K<SUB>m<UP>GSP</UP></SUB><UP>/</UP>[<UP>ROOH</UP>])
<UP>d</UP>[<UP>ROH</UP>]=k<SUB>1</SUB>[<UP>ROOH</UP>]([<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP>]+[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>])
 +R<SUB><UP>GC</UP></SUB>k<SUB>5</SUB>[<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr</UP><SUB>0</SUB>]/(1+K<SUB>m<UP>GSP</UP></SUB><UP>/</UP>[<UP>ROOH</UP>]) (Eq. 10)
<UP>d</UP>[<UP>AH</UP>]<UP>/dt</UP>=<UP>−</UP>k<SUB>3</SUB>[<UP>AH</UP>]([<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr</UP>]+[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>])
 −k<SUB>4</SUB>[<UP>AH</UP>]([<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr</UP>]+[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>])
 −k<SUB>6</SUB>[<UP>AH</UP>]([<UP>E</UP>(<UP>III</UP>)<UP>/PPIX/Tyr*</UP>]+[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX*/Tyr*</UP>]
 +[<UP>E</UP>(<UP>IV</UP>)<UP>/PPIX/Tyr*</UP>]) (Eq. 11)
In this model, cyclooxygenase activity is a simple, saturable function (the Km value for arachidonate is KmAA) reflecting the rate constant (k5), the arachidonate concentration ([AA]), and the total concentration of enzyme forms with activated cyclooxygenase (E(III)/PPIX/Tyr*, E(IV)/PPIX*/Tyr*, and E(IV)/PPIX/Tyr*). The term for cyclooxygenase activity appears in Equations 8 and 9. Similarly, the glutathione peroxidase activity is a simple, saturable function reflecting the peroxide level ([ROOH]), the Km value for hydroperoxide, PGG2 (KmGSP), and the GSP activity (calculated from the ratio of added GSP units to added cyclooxygenase units, RGC), the cyclooxygenase specific activity (k5), and the initial PGHS concentration [E(III)/PPIX/Tyr0]). The term for GSP activity appears in Equations 9 and 10. The initial concentrations and parameter values for Equations 1-11 are shown in Table I. The value of k1 was based on measured values for the rate of Intermediate I formation with lipid hydroperoxides (19). A range of k2 values was tested, with the lower bound being the observed value for conversion of Intermediate I to Intermediate II in PGHS-1 ("Results" and Ref. 19). The rates for reduction of higher oxidation states of heme (k3 and k4) were consistent with the measured value for the overall rate of return to ferric heme with phenolic reducing cosubstrates (20). The value of k5 represents the turnover number calculated from a PGHS-1 cyclooxygenase specific activity of 100 µmol O2/min/mg protein. A range of k6 values were tested, as described under "Results." The value of k7 was set at 10-3 times that of k5 to fit the typical observation of about 1000 cyclooxygenase catalytic events before self-inactivation of PGHS-1 (21). Measured values were used for the cyclooxygenase Km for arachidonate (KmAA) and for the GSP Km for PGG2 (KmGSP) (21, 22).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Parameter values used for kinetic simulations


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reaction of PGHS-1 and -2 with EtOOH-- Reaction of PGHS-1 or PGHS-2 with the small hydrophilic peroxide, EtOOH, produced an initial rapid decrease in the Soret absorbance peaks of the resting holoenzymes (data not shown), reflecting the formation of Intermediate I (Scheme I). The observed rate for Intermediate I formation increased linearly with the EtOOH concentration for both PGHS-1 and -2 (Fig. 1A). The slopes of the lines fitted to the data in Fig. 1A were used to estimate k1 values of 3.4 × 106 M-1 s-1 for PGHS-1 and 0.5 × 106 M-1 s-1 for PGHS-2. Thus, the initial reaction of PGHS-1 with EtOOH was approximately 7-fold faster than the corresponding reaction of PGHS-2.


View larger version (19K):
[in this window]
[in a new window]
 
Scheme I.   Branched chain radical mechanism for PGHS peroxidase and cyclooxygenase catalysis based on a proposal by Ruf and colleagues (7). The letters to the right side of each enzyme intermediate indicate the redox state of the heme iron (III or IV), whether the porphyrin is in ground (PPIX) or free radical (PPIX*) state, and whether the cyclooxygenase active site tyrosine residue (Tyr385 in PGHS-1 and Tyr371 in PGHS-2) is in ground state (Tyr) or has a tyrosyl radical present (Tyr*). Einact represents self-inactivated enzyme, ROOH and ROH are hydroperoxide and the corresponding alcohol, e- is an electron donor (reducing cosubstrate), and AA is arachidonic acid.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Kinetics of PGHS-1 and -2 peroxidase reactions with EtOOH at 3.9 °C. A, effects of EtOOH concentration on the rate of Intermediate I formation in PGHS-1 () and PGHS-2 (black-square). Changes in resting enzyme levels were monitored at either 410 nm (PGHS-1) or 408 nm (PGHS-2). The enzyme concentrations were 0.5 µM heme after mixing. B, effects of EtOOH concentration on the rate of formation of Intermediate II for PGHS-1 () and PGHS-2 (black-square). Conditions were the same as those described above for A, except that the reactions were monitored at 424 nm. Details are described under "Materials and Methods."

Observations of the reactions with EtOOH at 424 nm, which reflect formation of Intermediate II (Scheme I), revealed different patterns for the two isoforms (Fig. 1B). With PGHS-1, the observed rate for Intermediate II formation initially increased with the EtOOH concentration, indicating that step 1 in the mechanism shown in Scheme I was rate-limiting. The observed rate leveled off above 100 µM EtOOH, indicating that step 2 in Scheme I became rate-limiting at higher peroxide levels. The plateau value estimated from fitting the data to a hyperbolic equation, 80 s-1, provides an estimate for the first order rate constant (k2) with PGHS-1. In contrast, with PGHS-2 the observed rate of Intermediate II formation increased linearly as the EtOOH level was raised, without any indication of a plateau, even at observed rates approaching 300 s-1 (Fig. 1B). Thus, the value of k2 for PGHS-2 in reaction with EtOOH must be well above 300 s-1, and conversion of Intermediate I to Intermediate II is clearly much faster for PGHS-2 than for PGHS-1.

Reaction of PGHS-1 and -2 with 15-HPETE-- Reaction of PGHS-1 and -2 with the fatty acid hydroperoxide, 15-HPETE, led to rapid formation of Intermediate I, as indicated by the decrease in the Soret absorbance (data not shown). The observed rate for Intermediate I formation increased linearly with 15-HPETE concentration for both PGHS isoforms (Fig. 2A). The second order rate constant (k1) estimated from the data was 2.3 × 107 M-1 s-1 for PGHS-1 and 2.5 × 107 M-1 s-1 for PGHS-2, indicating that the two isoforms have very similar reactivity with this lipid hydroperoxide. On the other hand, observations of the kinetics of Intermediate II formation revealed divergent behavior for PGHS-1 and -2. For PGHS-1, the observed rate for Intermediate II formation increased linearly at lower 15-HPETE concentrations but began to level off at peroxide concentrations above 100 µM, indicating that the second step in Scheme I was becoming rate-limiting (Fig. 2B). A plateau was not reached, due to dead time limitations of the stopped flow instrument, but fitting of the data to a hyperbolic equation indicated a k2 value of approximately 900 s-1. With PGHS-1, the observed rate of Intermediate II formation was slower than that for Intermediate I at all 15-HPETE levels. For PGHS-2, the observed rate of Intermediate II formation was indistinguishable from that for Intermediate I formation throughout the 15-HPETE concentration range tested (Fig. 2B, inset), indicating that the first step was always rate-limiting and precluding estimation of a k2 value. However, Intermediate II formation was so much faster for PGHS-2 than for PGHS-1 at all 15-HPETE levels used (Fig. 2B), so the k2 value must be much greater for PGHS-2 than PGHS-1.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Kinetics of PGHS-1 and -2 peroxidase reactions with 15-HPETE at 3.9 °C. A, effects of 15-HPETE concentration on the rate of Intermediate I formation in PGHS-1 () and PGHS-2 (black-square). B, effects of 15-HPETE concentration on the rate of formation of Intermediate II for PGHS-1 () and PGHS-2 (black-square). Inset, comparison of PGHS-2 data at 408 nm (open circle ) and 424 nm (). Conditions were as described in the legend to Fig. 1.

Reaction of PGHS-2 with PPHP-- The peroxidase intermediate kinetics of PGHS-2 were also examined with a second hydrophobic hydroperoxide, PPHP. The observed rate for formation of Intermediate I was essentially the same as that for Intermediate II at each of the PPHP levels tested (Fig. 3). This is the same result found for 15-HPETE (Fig. 2) and again indicates that the first step in Scheme I remained rate-limiting and that the value of k2 for PGHS-2 is quite large with both PPHP and 15-HPETE. The value of k1 for PGHS-2 with PPHP estimated from the data in Fig. 3 is 1 × 107 M-1 s-1, quite comparable with the value obtained with 15-HPETE above.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Kinetics of PGHS-2 peroxidase reaction with PPHP at 4 °C. Stopped flow kinetics were monitored at 406 nm () and at 424 nm (open circle ). Details are as described under "Materials and Methods."

Kinetic scan experiments were carried out for the reaction of PGHS-2 with PPHP to examine the spectral changes in more detail (Fig. 4). The Soret peak was found to simultaneously decrease in intensity and shift to longer wavelengths as the reaction proceeded, with one isosbestic point near 414 nm. This is in marked contrast to the behavior of PGHS-1 where the decrease in Soret intensity, which reflects conversion of resting enzyme to Intermediate I, occurred before the red shift, reflecting conversion of Intermediate I to Intermediate II (7, 19, 23). Further, in PGHS-1 there is an isosbestic point between resting enzyme and Intermediate I near 424 nm in reactions with lipid hydroperoxides (7, 19, 23), quite distinct from the isosbestic point observed at 414 nm for PGHS-2 (Fig. 4). The coordinated diminution and red shift of the Soret band observed during reaction of PGHS-2 with PPHP suggests that resting enzyme is converting to Intermediate II without significant transient accumulation of Intermediate I. This prominence of resting enzyme and Intermediate II as the principal species during reaction of PGHS-2 with PPHP is entirely consistent with the observation that the first step is rate-limiting for both hydrophobic hydroperoxides in the single wavelength stopped flow experiments (Figs. 2 and 3).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Spectral changes in the Soret region during reaction of PGHS-2 (0.6 µM) with PPHP (50 µM) at 4.2 °C. Stopped flow observations of the reaction kinetics were performed at 2 nm increments between 390 and 450 nm. The data were collated to obtain absorption spectra at 2-ms intervals during the reaction. The arrows indicate the direction of the absorbance changes as the reaction progressed. Details are as described under "Materials and Methods."

Effects of Intermediate II Formation Rate on Cyclooxygenase Kinetics-- Kinetic simulations were used to predict the effect of changes in the rate of Intermediate II formation on the overall cyclooxygenase kinetics, in particular the requirement of the cyclooxygenase for hydroperoxide activator. Experimentally, the hydroperoxide activator requirements for PGHS-1 and -2 are estimated from the sensitivities of the two cyclooxygenase activities to inhibition by added hydroperoxide scavenger enzyme, GSP (6). In this process, the cyclooxygenase velocity achieved by a fixed amount of PGHS is measured in the presence of increasing amounts of GSP. The ratio of added GSP activity to control cyclooxygenase activity (RGC) needed for complete cyclooxygenase suppression is used as an empirical measure of the efficiency of cyclooxygenase activation by hydroperoxide. The value of this end point RGC was found to be about 75 for PGHS-1 and 700 in PGHS-2 (6). Simulations of the cyclooxygenase kinetics were carried out by numerical integration of rate equations derived from a mechanistic model (Scheme II) as described under "Materials and Methods." Experimentally based estimates are available for each of the rate constants in the model except for k6, the rate of tyrosyl radical quenching by reducing cosubstrate.


View larger version (28K):
[in this window]
[in a new window]
 
Scheme II.   Branched chain radical mechanism used for computer simulation of PGHS reaction kinetics. This mechanism is adapted from that shown in Scheme I as described under "Materials and Methods". E(III)PPIX/Tyr is resting enzyme, E(IV)PPIX*/Tyr is Intermediate I (equivalent to Compound I), E(IV)/PPIX/Tyr is Compound II, E(IV)/PPIX/Tyr* is Intermediate II, E(III)/PPIX/Tyr* has a ferric heme and tyrosyl radical (not included in Scheme I), E(IV)PPIX*/Tyr* has a ferryl heme and both porphyrin and tyrosyl radicals (not included in Scheme I), and E(inact) is totally inactivated enzyme. The three enzyme intermediates with tyrosyl radical (Tyr*) are assumed to be competent for cyclooxygenase catalysis. AA is arachidonic acid, ROOH represents hydroperoxide (PGG2), and AH is reducing cosubstrate.

The sensitivity of the system to the value of k6 was explored using values of the other parameters appropriate for PGHS-1, including a value of 350 s-1 for k2. The simulations predicted that the cyclooxygenase activity becomes more easily suppressed by GSP as the k6 value increases, with the end point RGC value decreasing from about 130 for k6 = 1000 M-1 s-1 to about 7 for k6 = 2 × 104 M-1 s-1 (Fig. 5). The inverse relationship between the k6 value and the end point RGC is readily apparent from the inset in Fig. 5. A k6 value of 2000 M-1 s-1 predicted an end point RGC close to the experimentally observed value of 75 for PGHS-1 (6). The sensitivity of the system to the value of k2 then was explored with several values of k6 (Fig. 6). The end point RGC was predicted to increase as the k2 value was increased, with most of the change occurring between k2 values of 350 and 2000 s-1. Regardless of the k6 value chosen, at saturating k2 values the end point RGC reached a plateau about 50% over the value predicted for a k2 of 350 s-1 (Fig. 6).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Influence of k6 value on the sensitivity of cyclooxygenase activity to inhibition by added GSP. The cyclooxygenase kinetics were predicted by computer simulation for a fixed amount of PGHS in the presence of the varying amounts of GSP (indicated by the ratio RGC) with a k2 value of 350 s-1 and a k6 value of 1000 M-1 s-1 (black-square), 2000 M-1 s-1 (black-diamond ), 4000 M-1 s-1 (black-triangle), 8000 M-1 s-1 (), or 20000 M-1 s-1 (×). Details of the simulation procedure are as described under "Materials and Methods." Lines fitted to the points are extrapolated to the x axis to obtain the end point RGC values, which are presented in the inset as a function of the k6 value used.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Influence of k2 value on the sensitivity of cyclooxygenase activity to inhibition by added GSP. End point RGC values were predicted for the indicated k2 values by computer simulation of cyclooxygenase kinetics for a fixed amount of PGHS in the presence of the varying amounts of GSP, with k6 values of 250 M-1 s-1 (black-diamond ), 750 M-1 s-1 (), 2000 M-1 s-1 (black-square), or 4000 M-1 s-1 (black-down-triangle ). Details of the simulation procedure are as described in the legend to Fig. 5 and under "Materials and Methods."


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The cyclooxygenase activity of PGHS-1 has long been known to require hydroperoxides for initiation (24). This requirement for a hydroperoxide activator leads to a strong positive feedback loop because the cyclooxygenase product, PGG2, is itself a hydroperoxide (Scheme I). The feedback loop is thought to be comprised of the hydroperoxide-dependent generation of a tyrosyl radical (steps 1 and 2 in Scheme I) and the formation of additional hydroperoxide in cyclooxygenase catalysis itself (step 5 in Scheme I); the overall pattern is that of an autocatalytic branched chain reaction (25). More recently, it has been established that cyclooxygenase activity of PGHS-2 also requires a hydroperoxide activator (5, 6). The observation that the PGHS-2 cyclooxygenase is activated at hydroperoxide levels approximately 10-fold lower than those needed for PGHS-1 (6) indicates that the positive feedback loop is more efficient in PGHS-2 than in PGHS-1. This difference could conceivably originate at any of the steps in the feedback loop. Given the similar cyclooxygenase specific activities observed for the two human isoforms expressed in the same system (26), however, it seems unlikely that the more efficient activation in PGHS-2 is due to more efficient cyclooxygenase propagation (step 5 in Scheme I). Rather, attention focuses on differences in the formation (steps 1 and 2 in Scheme I) or dissipation (step 6 in Scheme I) of the catalytically active tyrosyl radicals on Tyr385 in PGHS-1 and on Tyr371 in PGHS-2.

Formation of the key tyrosyl radical is proposed to involve oxidized enzyme intermediates in the peroxidase cycle (7). The initial reaction with hydroperoxide at the heme site leads to a two-electron oxidation of resting enzyme to form Intermediate I (step 1 in Scheme I). This species is analogous to Compound I in horseradish peroxidase and carries one oxidizing equivalent on the ferryl iron and the other as a porphyrin free radical (23). The next step in the postulated activation process (step 2 in Scheme I) is an intramolecular electron transfer from a tyrosine residue in the cyclooxygenase site (Tyr385 of PGHS-1 and Tyr371 of PGHS-2) to the porphyrin, forming a tyrosyl radical and bringing the heme to one oxidizing equivalent above the resting state (7). This intramolecular electron transfer mechanistically links the cyclooxygenase and peroxidase catalytic cycles and distinguishes the PGHS isoforms from other heme-dependent peroxidases that do not have an oxygenase activity (27, 28).

The results presented here show that the rates of formation of Intermediate I during reaction of the two PGHS isoforms with the fatty acid hydroperoxide, 15-HPETE, are essentially the same (Fig. 2). Therefore, it is reasonable to expect similar behavior for PGG2, the relevant fatty acid hydroperoxide formed during cyclooxygenase catalysis with arachidonate. PGHS-1 does have a higher Intermediate I formation rate than PGHS-2 for reaction with EtOOH (Fig. 1), presumably reflecting structural differences between the isoforms at the peroxidase active site that favor interactions of PGHS-1 with small hydrophilic peroxides. The major kinetic difference between the two isoforms found in the present study was in the rate of formation of Intermediate II. The rate was much faster for PGHS-2 than for PGHS-1 with both hydrophilic and hydrophobic hydroperoxides (Figs. 1 and 2). For PGHS-1, formation of Intermediate I was rate-limiting at low hydroperoxide levels, whereas conversion of Intermediate I to Intermediate II was rate-limiting at higher peroxide levels. For PGHS-2, interconversion of Intermediate I to II was so fast that formation of Intermediate I was rate-limiting at all hydroperoxide levels tested, and there was no appreciable accumulation of Intermediate I (Fig. 4). Thus, it is clear that the final step in the process of cyclooxygenase activation by lipid hydroperoxide is distinctly faster in PGHS-2 than in PGHS-1.

Although PGHS-1 and -2 share 60% overall amino acid identity, the conservation is much higher in the regions around the peroxidase and cyclooxygenase active sites (2). The three-dimensional structures are also well conserved in the active sites, with differences in backbone positions of the two isoforms averaging less than 0.4 angstrom (8-10). As a result, there are no readily apparent structural differences in the vicinity of the heme and Tyr385 (Tyr371) in the available crystallographic data (8, 10) that explain the observed differences in the value of k2 in PGHS-1 and -2. It remains possible that the active site structures in the crystals differ from those of the active enzymes in solution or that differences in structural dynamics lead to the observed differences in electron transfer rate.

The potential effects of the faster rate of Intermediate II formation in PGHS-2 on overall cyclooxygenase kinetics need to be considered in the context of the cellular environment in which the PGHS isoforms operate. Most cells have a large excess of peroxide scavenging enzymes, such as GSP, over peroxide generating enzymes, such as the cyclooxygenases (21). This preponderance of peroxide scavenging capacity tends to keep the cellular hydroperoxide level well below those encountered in vitro and may thereby accentuate the impact of differences in activation efficiency. Indeed, analyzing the effects of added peroxide scavengers has revealed features of feedback activation by hydroperoxide that are not apparent in routine cyclooxygenase assays (22, 29, 30), and titration with GSP has been used to quantify the strength of the feedback loops in PGHS-1 and -2 (6). Kinetic modelling of the complex combination of PGHS and GSP is thus very useful in predicting how differences in individual rate constants might influence cyclooxygenase catalysis in vivo.

The kinetic behavior of systems containing both PGHS and GSP can readily be predicted using numerical integration of equations based on mechanistic models (6, 22), and so we used this approach to predict the effect of changes in the k2 value on the sensitivity of the cyclooxygenase to inhibition by hydroperoxide scavenger. The mechanistic model chosen for kinetic simulations (Scheme II and "Materials and Methods") is based on the branched chain tyrosyl radical mechanism proposed by Ruf and colleagues (Ref. 7; see also Scheme I). The mechanism was modified to include two additional intermediates (E(III)/PPIX/Tyr* and E(IV)/PPIX*/Tyr* in Scheme II) to permit redox cycle events at the peroxidase site to continue after generation of the tyrosyl radical in the cyclooxygenase site. A simple route to self-inactivation from intermediates containing a tyrosyl radical (E(III)/PPIX/Tyr*, E(IV)/PPIX*/Tyr*, and E(IV)/PPIX/Tyr*in Scheme II) was added. The values of all rate constants in the model, except k6, were based on experimental observations, and the value of k6 for PGHS-1 was constrained by measurements from reactions with GSP present (Fig. 5). Thus, the general features of the kinetic behavior predicted by the model should be reliable. Earlier simulations of the GSP/PGHS system (6, 22) were based on a simpler paradigm that did not specify the individual steps in peroxidase catalysis and thus was not useful in evaluating the effects of the k2 value on the kinetic behavior.

The simulation results predict that increases in k2 above the value of about 350 s-1 observed for PGHS-1 increase the resistance to inhibition by the peroxide scavenger by up to 50% (Fig. 6). This is less than the 8-fold difference in resistance to inhibition by GSP actually observed for the two cyclooxygenase activities (6). It thus appears that the increased rate of Intermediate II formation (k2) observed here for PGHS-2 compared with PGHS-1 can account for only part of the difference in hydroperoxide activation efficiency between the two isoforms. The simulation results also indicate that the resistance of the cyclooxygenase activity to inhibition by GSP is quite sensitive to the stability of the tyrosyl radical in Intermediate II, with the resistance increasing as the value of the k6 rate constant was decreased (Fig. 5). With a k6 value of 250 M-1 s-1 and a k2 value of about 2000 s-1, the predicted end point RGC value was above 600 (Fig. 6), close to the end point RGC value of 650 actually observed for human PGHS-2 (6). The ability of the mechanistic model to simulate the GSP sensitivity of PGHS-2 once the k6 value is decreased suggests that the active site tyrosyl radical in PGHS-2 is less readily quenched by reducing cosubstrates than the corresponding tyrosyl radical in PGHS-1. Electron paramagnetic resonance kinetic measurements will be needed to test this intriguing possibility that differing tyrosyl radical stabilities in the two PGHS isoforms also contribute to the difference in hydroperoxide activator efficiency.

    ACKNOWLEDGEMENTS

We thank Wei Chen and Dr. Gang Wu for help preparing of PGHS-1 and -2 and Dr. David Swinney at Roche Bioscience for providing the PGHS-2 sample used for reaction with PPHP.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants GM 52170 (to R. J. K.) and GM 44911 (to A.-L. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Internal Medicine, University of Texas Health Science Center at Houston, MSB5.284, 6431 Fannin St., Houston, TX 77030. Tel.: 713-500-6772; Fax: 713-500-6810; E-mail: kulmacz{at}heart.med.uth.tmc.edu.

    ABBREVIATIONS

The abbreviations used are: PGHS, prostaglandin H synthase; PGG2, prostaglandin G2; EtOOH, ethyl hydrogen peroxide; 15-HPETE, 15-hydroperoxyeicosatetraenoic acid; PPHP, trans-5-phenyl-4-pentenyl-1-hydroperoxide; GSP, glutathione peroxidase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Samuelsson, B., Goldyne, M., Granström, E., Hamberg, M., Hammarström, S., and Malmsten, C. (1978) Annu. Rev. Biochem. 47, 997-1029[CrossRef][Medline] [Order article via Infotrieve]
  2. Smith, W. L., and DeWitt, D. L. (1996) Adv. Immunol. 62, 167-215[Medline] [Order article via Infotrieve]
  3. Herschman, H. R. (1996) Biochim. Biophys. Acta 1299, 125-140[Medline] [Order article via Infotrieve]
  4. Kulmacz, R. J. (1998) FEBS Lett. 430, 154-157[CrossRef][Medline] [Order article via Infotrieve]
  5. Capdevila, J. H., Morrow, J. D., Belosludtsev, Y. Y., Beauchamp, D. R., DuBois, R. N., and Falck, J. R. (1995) Biochemistry 34, 3325-3337[Medline] [Order article via Infotrieve]
  6. Kulmacz, R. J., and Wang, L.-H. (1995) J. Biol. Chem. 270, 24019-24023[Abstract/Free Full Text]
  7. Dietz, R., Nastainczyk, W., and Ruf, H. H. (1988) Eur. J. Biochem. 171, 321-328[Abstract]
  8. Picot, D., Loll, P. J., and Garavito, R. M. (1994) Nature 367, 243-249[CrossRef][Medline] [Order article via Infotrieve]
  9. Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., and Browner, M. F. (1996) Nat. Struct. Biol. 3, 927-933[Medline] [Order article via Infotrieve]
  10. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., Miyashiro, J. M., Penning, T. D., Seibert, K., Isakson, P. C., and Stallings, W. C. (1996) Nature 384, 644-648[CrossRef][Medline] [Order article via Infotrieve]
  11. Tsai, A.-L., Hsi, L. C., Kulmacz, R. J., Palmer, G., and Smith, W. L. (1994) J. Biol. Chem. 269, 5085-5091[Abstract/Free Full Text]
  12. Goodwin, D. C., Gunther, M. R., Hsi, L. C., Crews, B. C., Eling, T. E., Mason, R. P., and Marnett, L. J. (1998) J. Biol. Chem. 273, 8903-8909[Abstract/Free Full Text]
  13. Kulmacz, R. J., and Lands, W. E. M. (1987) in Prostaglandins and Related Substances: A Practical Approach (Benedetto, C., McDonald-Gibson, R. G., Nigam, S., and Slater, T. F., eds), pp. 209-227, IRL Press, Washington, D.C.
  14. Peterson, G. L. (1983) Methods Enzymol. 91, 95-119[Medline] [Order article via Infotrieve]
  15. Kulmacz, R. J., Tsai, A.-L., and Palmer, G. (1987) J. Biol. Chem. 262, 10524-10531[Abstract/Free Full Text]
  16. Graff, G., Anderson, L. A., and Jaques, L. W. (1990) Anal. Biochem. 188, 38-47[Medline] [Order article via Infotrieve]
  17. Porter, N. A., Logan, J., and Kontoyiannidou, V. (1979) J. Org. Chem. 44, 3177-3181
  18. Kulmacz, R. J., Ren, Y., Tsai, A.-L., and Palmer, G. (1990) Biochemistry 29, 8760-8771[Medline] [Order article via Infotrieve]
  19. Tsai, A.-L., Wei, C., Baek, H. K., Kulmacz, R. J., and Van Wart, H. E. (1997) J. Biol. Chem. 272, 8885-8894[Abstract/Free Full Text]
  20. Hsuanyu, Y., and Dunford, H. B. (1992) J. Biol. Chem. 267, 17649-17657[Abstract/Free Full Text]
  21. Marshall, P. J., Kulmacz, R. J., and Lands, W. E. M. (1987) J. Biol. Chem. 262, 3510-3517[Abstract/Free Full Text]
  22. Kulmacz, R. J., and Lands, W. E. M. (1983) Prostaglandins 25, 531-540[CrossRef][Medline] [Order article via Infotrieve]
  23. Lambeir, A.-M., Markey, C. M., Dunford, H. B., and Marnett, L. J. (1985) J. Biol. Chem. 260, 14894-14896[Abstract/Free Full Text]
  24. Smith, W. L., and Lands, W. E. M. (1972) Biochemistry 11, 3276-3285[Medline] [Order article via Infotrieve]
  25. Wei, C., Kulmacz, R. J., and Tsai, A.-L. (1995) Biochemistry 34, 8499-8512[Medline] [Order article via Infotrieve]
  26. Barnett, J., Chow, J., Ives, D., Chiou, M., Mackenzie, R., Osen, E., Nguyen, B., Tsing, S., Bach, C., Freire, J., Chan, H., Sigal, E., and Ramesha, C. (1994) Biochim. Biophys. Acta 1209, 130-139[Medline] [Order article via Infotrieve]
  27. Tsai, A.-L., Kulmacz, R. J., and Palmer, G. (1995) J. Biol. Chem. 270, 10503-10508[Abstract/Free Full Text]
  28. Tsai, A.-L., Palmer, G., Xiao, G., Swinney, D. C., and Kulmacz, R. J. (1998) J. Biol. Chem. 273, 3888-3894[Abstract/Free Full Text]
  29. Hemler, M. E., Graff, G., and Lands, W. E. M. (1978) Biochem. Biophys. Res. Commun. 85, 1325-1331[Medline] [Order article via Infotrieve]
  30. Hemler, M. E., Cook, H. W., and Lands, W. E. M. (1979) Arch. Biochem. Biophys. 193, 340-345[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.